Mutaflor®

Escherichia coli strain Nissle 1917

Yomogi®

Saccharomyces cerevisiae boulardii – HANSEN CBS 5926

Infloran®

Bifidobacterium bifidum NCDO 2203 & Lactobacillus acidophilus NCDO 1748
Mutaflor®
Escherichia coli strain Nissle 1917

Manufactured in Germany and in use for over 102 years, a single strain human commensal with properties and characteristics that has made this one of the best researched bacterial strains.
Mutaflor® Escherichia coli strain Nissle 1917 (EcN) is the only probiotic to be AUST R registered in Australia and is included as a probiotic with established efficacy in the
2018 Gastroenterological Society of Australia – Clinical Update for General Practitioners and  Physicians, Inflammatory Bowel Disease 

Learn More

Yomogi®
Saccharomyces cerevisiae boulardii – HANSEN CBS 5926

Also manufactured in Germany by Ardeypharm, Yomogi is a medicinal yeast with distinct probiotic properties. Saccharomyces cerevisiae boulardii – HANSEN CBS 5926 is the particular strain used in most clinical and pharmacological studies to support its use.

Learn More

Infloran®
Bifidobacterium bifidum NCDO 2203  & Lactobacillus acidophilus NCDO 1748

Manufactured in Italy by Laboratorio Farmaceutico SIT, Infloran is a probiotic that was previously only found in Australian and New Zealand Neonatal Intensive Care Units. Infloran was carefully chosen to prevent a condition known as Necrotising Enterocolitis (NEC) in preterm births and aligns with the principles of probiotic supplementation.
Both Bifidobacterium and Lactobacillus are the predominated bacterial species of healthy breastfed infants and Infloran has clearly demonstrated its efficacy and safety in this population.
Learn More

Evidence Based Probiotics – Proven clinical efficacy

The role of our gut microbiota, its influence on our health and indeed its role in disease is well established.
Probiotic supplementation from a clinical perspective is based on a number of factors

  • Do no harm
  • Careful selection of specific strains with evidence demonstrating ability to alter health outcomes
Characteristics required
  • resistance to gastric acidity
  • ability to colonise and support beneficial intestinal bowel flora
  • antimicrobial properties – antagonistic properties toward pathogens
  • mucosal integrity, contributing to luminal metabolism and stability
  • anti-inflammatory and immunomodulatory effects
  • promote and enhance healthy digestive function
    Together with our European partners, we are dedicated to bringing and making available evidence-based medications with many potential applications.Always read the label and use only as directed. If symptoms persist, talk to your doctor or healthcare professional.

Upcoming Events

There are no upcoming events at this time.
Contact Info

Suite 4, 74 Prospect Road, Prospect, SA

PO BOX 7302 West Lakes SA 5021

1300 819 765

Int +61 8 7127 1519

1300 819 423

admin@evidencebasedprobiotics.com.au

Send us a Message